Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
Yunpeng Yang(Sun Yat-sen University), Li Zhang(Jinan Stomatological Hospital), Weineng Feng(First People's Hospital of Foshan), Giovanni Selvaggi, Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Shundong Cang(Henan University), Yi Hu(Union Hospital), Zhendong Zheng(General Hospital of Shenyang Military Region), Yanqiu Zhao(Henan Cancer Hospital), Xiaobin Yuan(Betta Pharmaceuticals (China)), Youling Gong(Dalian Medical University), Kewei Ma(Jilin University), Wei Song(Xuzhou Medical College), Zhilin Shen(Betta Pharmaceuticals (China)), Shijun Zhao(Second Hospital of Shandong University), Shanshan Xiao(Central South University), Yubiao Guo(Sun Yat-sen University), Jian Fang(Peking University), Jianhua Chen(Xinjiang Medical University), Feng Ye(Shanghai Sunshine Rehabilitation Center), Yuan Chen(China General Nuclear Power Corporation (China)), Tao Wang(Pfizer (United States)), Yong Song(Nanjing General Hospital of Nanjing Military Command), Zhuang Yu(Shanghai East Hospital), Jing Zheng(Zhejiang University), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Gaofeng Li(Sir Run Run Shaw Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Yiping Zhang(Zhejiang Cancer Hospital), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Huijie Wang(China Medical University), Jie Huang(Sun Yat-sen University), Li Mao(Washington State University), Ning Wu(Regeneron (United States)), Gang Wu(Union Hospital), Lieming Ding(Betta Pharmaceuticals (China)), Wu Zhuang(Hunan University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Larry Zhu(Betta Pharmaceuticals (China)), Xiaoqing Liu(Chinese PLA General Hospital), Jianya Zhou(First Affiliated Hospital Zhejiang University)
Cited by 44
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k